We are monitoring the impact of COVID-19 & Recession alarm on Europe Psoriasis Drugs Market Get in touch with us for detailed analysis Know More
Share on

Europe Psoriasis Drugs Market Research Report - Segmented By Drug Type, Route of Administration, Target, & Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic & Rest of Europe) - industry Analysis on Size, Share, Trends and Growth Forecast (2022 to 2027)

Published: January, 2022
ID: 1637
Pages: 140

Europe Psoriasis Drugs Market Size (2022 to 2027)

The size of the European Psoriasis Drugs Market is expected to worth USD 4.23 billion by 2027 from USD 2.96 billion in 2022, showcasing a CAGR of 7.36% from 2022 to 2027.

Psoriasis is no communicable inflammatory skin condition that alters the life cycle of skin cells by speeding up the growth of cells on the skin's surface. The rapid development of cells produces thick, silvery scales and makes the skin red, dry, flaky, and itchy. Currently, no permanent cure is available for the disease,

However, preventative measures can be adopted to slow down skin cells' growth on the surface of the skin. Psoriasis can be treated either with pharmaceuticals or biopharmaceuticals therapies through the topical and systemic process.

These medications are administered either by applying on the skin or consumed orally or through injections that specifically block parts of the immune system by specifically targeting Tumor Necrosis Factor, Phosphodiesterase Type 4, Interleukin, among others. In Europe, approximately 3.7 million people are affected by psoriasis as per the European Federation of Pharmaceutical Industries and Associations.

The growth of the Psoriasis Drugs market is majorly driven by factors such as increasing public awareness, approval of new drugs (interleukin-17 inhibitor, Taltz - ixekizumab by Eli Lily), and boost in psoriasis Research and Development investment. The key restraints of the market are the high cost involved in drug development, patent expiry of brand name drugs, side effects from the systemic and biologics medication, and health insurance issue.

This research report on the European Psoriasis Drugs Market has been segmented and sub-segmented into the following categories:

By Drug Type:

  • Pharmaceuticals
  • Biopharmaceuticals

By Route of Administration: 

  • Topical
  • Systemic
    • Oral
    • Intravenous
    • Others

By Target: 

  • Tumour Necrosis Factor (TNF)
  • Phosphodiesterase Type 4 (PDE4)
  • Interleukin

By Country: 

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

Prominent companies dominating the European Psoriasis Drugs Market profiled in this report are Johnson & Johnson (USA), Novartis International AG (Switzerland), Pfizer Inc (USA), Merck and Co. Inc (USA), Celgene Corporation (USA), Janssen Biotech Inc (USA), Stiefel Laboratories Inc (USA), Takeda Pharmaceutical Company Limited (Japan), Amgen (USA), and AbbVie (USA).


                1.1 Market Definition     

                1.2 Study Deliverables   

                1.3 Base Currency, Base Year and Forecast Periods   

                1.4 General Study Assumptions 

2. Research Methodology                    

                2.1 Introduction        

                2.2 Research Phases       

2.2.1 Secondary Research                           

2.2.2 Primary Research                 

2.2.3 Econometric Modelling                      

2.2.4 Expert Validation                  

                2.3 Analysis Design  

                2.4 Study Timeline   

3. Overview                

                3.1 Executive Summary 

                3.2 Key Inferences  

                3.3 Epidemology       

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)             

                4.1 Market Drivers   

                4.2 Market Restraints     

                4.3 Key Challenges  

                4.4 Current Opportunities in the Market       

5. Market Segmentation                       

                5.1 Drug Type    

5.1.1 Introduction                           

5.1.2 Pharmaceuticals                   

5.1.3 Biopharmaceuticals                             

5.1.4  Y-o-Y Growth Analysis, By Drug Type                          

5.1.5  Market Attractiveness Analysis, By Drug Type                        

5.1.6  Market Share Analysis, By Drug Type                         

                5.2 Route of Administration

5.2.1 Introduction                           

5.2.2 Topical                      

5.2.3 Systemic                  




5.2.4  Y-o-Y Growth Analysis, By Route of Administration                              

5.2.5  Market Attractiveness Analysis, By Route of Administration                            

5.2.6  Market Share Analysis, By Route of Administration                             

                5.3 Target    

5.3.1 Introduction                           

5.3.2 Tumour Necrosis Factor (TNF)                        

5.3.3 Phosphodiesterase Type 4 (PDE4)                

5.3.4 Interleukin                              

5.3.5 Others                      

5.3.6  Y-o-Y Growth Analysis, By Target                 

5.3.7  Market Attractiveness Analysis, By Target                               

5.3.8  Market Share Analysis, By Target                 

6. Geographical Analysis                       

                6.1 Introduction        

6.1.1 Regional Trends                    

6.1.2 Impact Analysis                     

6.1.3 Y-o-Y Growth Analysis                        
 By Geographical Area     
 By Product           
 By Type 
 By Application    
 By Indication       

6.1.4  Market Attractiveness Analysis                     
 By Geographical Area     
 By Product           
 By Type 
 By Application    
 By Indication       

6.1.5  Market Share Analysis                      
 By Geographical Area     
 By Product           
 By Type 
 By Application    
 By Indication       

                6.2 U.K  

                6.3 Spain      

                6.4 Germany      

                6.5 Italy        

                6.6 France   

7.Strategic Analysis                 

                7.1 PESTLE analysis  

7.1.1 Political                     

7.1.2 Economic                 

7.1.3 Social                         

7.1.4 Technological                         

7.1.5 Legal                          

7.1.6 Environmental                       

                7.2 Porter’s Five analysis       

7.2.1 Bargaining Power of Suppliers                        

7.2.2 Bargaining Power of Consumers                    

7.2.3 Threat of New Entrants                     

7.2.4 Threat of Substitute Products and Services                              

7.2.5 Competitive Rivalry within the Industry                     

8.Market Leaders' Analysis                  

                8.1 Johnson & Johnson  

8.1.1 Overview                 

8.1.2 Product Analysis                   

8.1.3 Financial analysis                  

8.1.4 Recent Developments                       

8.1.5 SWOT analysis                       

8.1.6 Analyst View                          

                8.2 Novartis International AG     

                8.3 Pfizer Inc      

                8.4 Merck and Co. Inc     

                8.5 Celgene Corporation       

                8.6 Janssen Biotech Inc          

                8.7 Stiefel Laboratories Inc   

                8.8 Takeda Pharmaceutical Company Limited      

                8.9 Amgen  

                8.10 AbbVie        

9.Competitive Landscape                     

                9.1 Market share analysis     

                9.2 Merger and Acquisition Analysis

                9.3 Agreements, collaborations and Joint Ventures  

                9.4 New Product Launches  

10.Market Outlook and Investment Opportunities                   


                a) List of Tables 

                b) List of Figures       

  1. Europe Psoriasis Drugs Market, By Systemic, From 2022 - 2027 (USD Billion)
  2. Europe Oral Systemic Route Market, By Region, From 2022 - 2027 (USD Billion)
  3. Europe Intravenous Systemic Route Market, By Region, From 2022 - 2027 (USD Billion)
  4. Europe Others Systemic Route Market, By Region, From 2022 - 2027 (USD Billion)
  5. U.K. Psoriasis Drugs Market, By Systemic, From 2022 - 2027 (USD Billion)
  6. Germany Psoriasis Drugs Market, By Systemic, From 2022 - 2027 (USD Billion)
  7. France Psoriasis Drugs Market, By Systemic, From 2022 - 2027 (USD Billion)
  8. Italy Psoriasis Drugs Market, By Systemic, From 2022 - 2027 (USD Billion)
  9. Spain Psoriasis Drugs Market, By Systemic, From 2022 - 2027 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports




pdf excel


pdf excel powerbi




What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.

Talk to our analyst and get customised report done according to your research needs


Check if you can avail any discount. Submit your details and our team will get back to you.


Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 3335

Didn’t find what you’re looking for?

Find it too expensive?

Click for Request Sample